Table 3.
Per-person survival benefits, numbers of patients with AIDS entering care, and era-specific and cumulative survival benefits.
| Year | Intervention | Mean survival benefit per persona | Patients with AIDS entering care, no. | Patients surviving to next treatment era, % | Infections averted, no. | Total survival benefit, years |
|---|---|---|---|---|---|---|
| HIV disease treatment | ||||||
| 1989–1992 | PCP prophylaxis | 3.1 months | 158,370 | 33 | … | 40,912 |
| 1993–1995 | PCP/MAC prophylaxis | 24.4 months | 226,458 | 39 | … | 460,465 |
| 1996–1997 | PCP/MAC prophylaxis and ART 1 | 93.7 months | 72,716 | 86 | … | 567,788 |
| 1998–1999 | PCP/MAC prophylaxis and ART 2 | 132.6 months | 52,702 | 93 | … | 582,359 |
| 2000–2002 | PCP/MAC prophylaxis and ART 3 | 138.8 months | 71,946 | 91 | … | 832,179 |
| 2003 | PCP/MAC prophylaxis and ART 4 | 159.9 months | 24,780 | … | … | 330,189 |
| Subtotal | 2,813,892 | |||||
| PMTCT | ||||||
| 1994–1999 (pMTCT-ZDV) | Child receives OI prophylaxis and ZDV monotherapy | 60.5 years | … | … | 223 | 51,646 |
| 1994–1999 (pMTCT-ZDV) | Child receives OI prophylaxis and combination ART | 45.8 years | … | … | 833 | … |
| 2000–2003 (pMTCT-cART) | Child receives OI prophylaxis and combination ART | 46.7 years | … | … | 1839 | 85,833 |
| Subtotal | 137,479 | |||||
| Total | 2,951,371 | |||||
NOTE. cART, combination antiretroviral therapy; MAC, Mycobacterium avium complex; OI, opportunistic infection; PCP, Pneumocystis jirovecii; pMTCT, prevention of mother-to-child transmission; ZDV, zidovudine. Adapted from [35].
a
Data are reported as weighted averages of the per-person survival benefit among individuals receiving care, derived from each year in the current treatment era, and reflect changes in both the life expectancy of HIV-positive patients and the general US population over time.